A family office invests from an evergreen fund focused on seed to later-stage companies building infrastructure and value chains around big data, including but not limited to health and life science data. Typical investment sizes range from $250K – $1M for early-stage companies. Additional capital for follow-on investments is available for portfolio companies. Along with capital, the firm also provides access to their Asian network for later-stage companies needing market expansion (once all other aspects of the company’s business have been resolved). There is not a requirement for a board seat along with investments. The fund is focused on U.S. companies (with a focus on Silicon Valley), but will consider companies globally.
The firm invests in companies that are creating solutions to close the data feedback loop, including capturing data, analytics and instruments/robotics. The firm is interested in medical devices, diagnostics and healthcare IT products, with addressable markets of at least $1B. In the diagnostics field, m-health devices and genomics are of particular interest. AME is open to all sub-sectors of health IT including consumer-facing hardware/software, data collection/management and data analytics. The firm will invest in medical devices and diagnostics that require FDA approval, with 510K regulatory pathway being the most common, although devices/services that require different regulatory pathways will also be considered. Companies developing hardware or robotics that automate scientific life science experiments are also of interest. The firm does not make any investments in therapeutics.
There are no formal requirements for management teams, but management teams with experience commercializing products are preferred.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org